Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06830889 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy

StatusRecruiting
PhasePhase 3
Started2025-06-03
View on ClinicalTrials.gov ↗

Amendment history

2026-01-20
Study Status v3
Start date2025-06-09→2025-06-03
2025-06-23
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2025-05→confirmed 2025-06-09
Study sitesdetails revised at 2 of 2 sites
2025-02-16
Study Status, Oversight, Conditions v1
Re-verified, no change to tracked fields
2025-02-12
Original filing
This trial is a registered phase III, randomized, open-label, multicenter study designed to evaluate the efficacy and safety of BL-M07D1 in the adjuvant treatment of HER2-positive breast cancer with residual invasive cancer after neoadjuvant therapy.
Trial Details
NCT Number NCT06830889
Lead Sponsor Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Conditions HER2-positive Breast Cancer
Enrollment 1,450 participants
Start Date 2025-06-03
Primary Completion 2031-10 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-22